sciencewerkedx
SciencewerkeDX is a Singapore-based B2B distributor of proprietary genetic, molecular, and pharmacogenetic diagnostic tests across Southeast Asia, serving doctors, hospitals, and clinical laboratories through exclusive regional partnerships with leading diagnostic manufacturers including Myriad Genetics, Genomind, CENTOGENE, and TechLab.
- Company typePrivate
- Founded2005
- HeadquartersSingapore, Singapore
- Headcount—
- GTM typeB2B
- OfferingServices
What sciencewerkedx does
SciencewerkeDX is a Singapore-headquartered medical diagnostics distribution company operating as a division of Sciencewerke Pte Ltd. The company functions as a B2B sales-led channel partner that distributes proprietary genetic, molecular, and pharmacogenetic diagnostic tests to healthcare providers across Southeast Asia. Its customer base comprises doctors, hospitals, clinical laboratories, and indirectly patients and their families, with marketing conducted through webinars, educational video content, news articles, and direct sales representative engagement.
The product portfolio is assembled through distribution agreements with multiple market-leading diagnostic manufacturers rather than developed in-house. Core partnerships include Myriad Genetics (distributing the myRisk 48-gene hereditary cancer panel, BRACAnalysis, Prolaris for prostate cancer prognosis, EndoPredict for breast cancer prognosis, and myChoice HRD), Genomind (Professional PGx Express pharmacogenomic testing for psychiatric medications), CENTOGENE (CentoXome whole exome sequencing for rare disease diagnosis), and TechLab (enteric disease diagnostics including C. DIFF QUIK CHEK, lactoferrin tests, and H. PYLORI QUIK CHEK). Additional partnerships with BrainsWay (Deep TMS neurostimulation therapy), Xstrahl (radiotherapy solutions), and CredoDx Biomed (QubeMDx+ veterinary diagnostics) extend the company's reach into treatment devices and animal health. The diagnostic technologies span multiple modalities including gene expression profiling, next-generation sequencing, membrane enzyme immunoassays, ELISA, and transcranial magnetic stimulation.
Revenue is generated through one-time test and kit sales to healthcare institutions and clinicians, with pricing not publicly disclosed and varying by region, test type, and buyer. The company operates from a single office at 100G Pasir Panjang Rd in Singapore and serves markets in Singapore, Malaysia, and Mauritius. The business is privately held within the Sciencewerke Pte Ltd corporate group, with no external venture capital, private equity, or public shareholders disclosed in available materials. The company has executed product upgrades and enhancements periodically, including a June 2021 enhancement of the CentoXome WES solution and an April 2023 upgrade of the Genomind Professional PGx report with two new statin gene analyses.
sciencewerkedx firmographics
Firmographics- Name
- sciencewerkedx
- Legal name
- Sciencewerke Pte Ltd
- Website
- https://sciencewerkedx.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Short description
- SciencewerkeDX is a Singapore-based B2B distributor of proprietary genetic, molecular, and pharmacogenetic diagnostic tests across Southeast Asia, serving doctors, hospitals, and clinical laboratories through exclusive regional partnerships with leading diagnostic manufacturers including Myriad Genetics, Genomind, CENTOGENE, and TechLab.
- Ownership category
- akta.pro rank
sciencewerkedx industry classification
Industry- Product category
- Medical Diagnostic Services
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
- akta.pro secondary industries
- Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Pharmacogenomics (PGx) Decision Support (HLAAANAB), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)
Keywords
Where sciencewerkedx is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
sciencewerkedx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Diagnostic Test Distribution: SciencewerkeDX distributes proprietary genetic and molecular diagnostic tests from partner companies to healthcare providers (doctors, hospitals, patients). Revenue appears to be generated through the sale of diagnostic testing kits and services to healthcare institutions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
sciencewerkedx product offering
Product offeringCore offering
SciencewerkeDX is a division of Sciencewerke Pte Ltd that distributes proprietary genetic, molecular, pharmacogenomic, enteric, and neurostimulation diagnostic products supplied by partner diagnostic companies. Its portfolio supports doctors, hospitals, patients, and families with tests for cancer risk and prognosis, psychiatric medication optimization, rare genetic disorders, enteric disease, depression treatment, radiotherapy treatment planning, and veterinary pathogen detection.
Product overview
SciencewerkeDX, a division of Sciencewerke Pte Ltd, operates as a diagnostic distribution company offering a portfolio of proprietary genetic and molecular diagnostic tests across multiple medical specialties. The product portfolio centers on hereditary cancer testing (myRisk™, BRACAnalysis®, Prolaris®, EndoPredict®, myChoice HRD), pharmacogenomics (Genomind Professional PGx Express™), neurostimulation therapy (Deep TMS with BrainsWay), and enteric disease diagnostics (TECHLAB products including C. DIFF QUIK CHEK COMPLETE®, H. PYLORI QUIK CHEK™, lactoferrin tests). Additional offerings include rare disease genetic testing (CentoXome Whole Exome Sequencing) and veterinary diagnostics (QubeMDx+™). The company functions as a distributor and service provider, working with market-leading diagnostic manufacturers to provide actionable genetic tests for better medical management and treatment decisions.
Differentiator
Problem solved
Functional benefit
Brands
- myRisk: Hereditary Cancer Syndrome test panel - identifies elevated risk for 8-11 important cancers by analyzing multiple clinically actionable genes
- Prolaris
- EndoPredict
- LACTOFERRIN EZ VUE
- LEUKO EZ VUE
- C. DIFF QUIK CHEK
- H. PYLORI QUIK CHEK
Products and services
- myRisk™ (11 Cancer Panel) Hereditary cancer panel test that identifies elevated risk for 11 important cancers by analyzing multiple clinically actionable genes and combining genetic test status with personal cancer family history.
- EndoPredict® Prognostic gene expression test to determine risk of distant metastases in patients with estrogen receptor positive, HER2-negative primary breast cancer, helping determine whether chemotherapy is needed.
- Prolaris® Prostate cancer prognostic test that measures expression of genes involved with tumor proliferation to predict disease aggressiveness in conjunction with clinical parameters.
- Genomind Professional PGx Express™ Pharmacogenomic testing service that analyzes genetic variants to inform treatment recommendations for antidepressants, antipsychotics, and other medications to reduce adverse drug reactions.
- Deep Transcranial Magnetic Stimulation (TMS) Brain stimulation therapy using Deep TMS technology for treatment of depression, including the SWIFT accelerated protocol for faster treatment.
- C. DIFF QUIK CHEK COMPLETE® Rapid membrane enzyme immunoassay for simultaneous detection of Clostridium difficile glutamate dehydrogenase antigen and toxins A and B in fecal specimens.
- H. PYLORI QUIK CHEK™ Rapid membrane enzyme immunoassay for qualitative detection of Helicobacter pylori specific antigen in human fecal specimens.
- LACTOFERRIN EZ VUE® Immunochromatographic test for qualitative detection of elevated fecal lactoferrin levels as a marker for intestinal inflammation and active inflammatory bowel disease.
- LEUKO EZ VUE® Immunochromatographic test for qualitative detection of elevated fecal lactoferrin levels to determine the presence of intestinal inflammation in acute intestinal illnesses.
- LACTOFERRIN SCAN® Quantitative ELISA for measuring concentrations of fecal lactoferrin to distinguish active inflammatory bowel disease from noninflammatory irritable bowel syndrome.
- CentoXome - Whole Exome Sequencing Whole Exome Sequencing solution for diagnosing rare genetic disorders, providing comprehensive genetic analysis for patients with unknown genetic conditions.
- myChoice HRD Homologous recombination deficiency test for ovarian cancer patients to identify those who may benefit from PARP inhibitor treatment.
- QubeMDx+™ Veterinary molecular diagnostic solution using real-time PCR technology for rapid detection of multiple veterinary pathogens in animals.
- BRACAnalysis® Genetic test for hereditary breast and ovarian cancer risk assessment analyzing BRCA1 and BRCA2 genes.
Quantifiable outcome
- Myriad myRisk increases mutation detection by 40-50% in patients appropriate for HBOC or Lynch testing
- +2 more outcomes
Companies that use sciencewerkedx
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles3 records
sciencewerkedx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
sciencewerkedx partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Myriad GeneticscoreSciencewerkeDX distributes Myriad's hereditary cancer testing products including myRisk (48-gene panel), Prolaris (prostate cancer prognosis), EndoPredict (breast cancer prognosis), and myChoice HRD (homologous recombination deficiency testing).
- GenomindcoreDistribution partner for Genomind pharmacogenomics testing products including Professional PGx Express for psychiatric medication optimization based on genetic profiles.
- CENTOGENEcorePartners for rare disease genetic testing solutions including CentoXome (whole exome sequencing), CentoTalk educational content, and prenatal genetic testing products.
- TechLabcoreDistribution of TechLab's intestinal inflammation and enteric disease diagnostics including C. difficile testing products, lactoferrin tests, H. pylori tests, and related diagnostic assays.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
sciencewerkedx competitors and assessment
Company assessmentDirect peers
- Prenetics: Hong Kong-headquartered genetic and molecular diagnostic testing company with strong Asia-Pacific consumer and clinical presence. Highly comparable to SciencewerkeDX as both serve APAC markets with genetic/molecular tests distributed to healthcare providers and consumers.
- Mirxes: Singapore-based molecular diagnostics company developing and commercializing RNA-based cancer detection tests across Asia. Comparable as a Singapore-headquartered molecular diagnostics company targeting healthcare providers in APAC.
- ACT Genomics: Taiwan-based cancer genomics company offering NGS-based profiling, hereditary cancer testing, and companion diagnostics across Asia. Comparable for cancer-focused molecular and hereditary diagnostic test distribution in the APAC region.
- Macrogen: South Korea-headquartered genomics services company providing NGS, molecular diagnostics, and clinical genetic testing across Asia. Comparable as an Asia-based distributor/services provider of molecular and genetic diagnostics.
- Novogene: China-headquartered genomics services company offering NGS-based testing, clinical diagnostics, and translational research services across Asia-Pacific. Comparable for molecular and genetic diagnostic services distribution in APAC.
Broad incumbents
- Eurofins Scientific: Global leader in bioanalytical testing and clinical diagnostics services, including genetic and molecular diagnostics. Comparable as a broad incumbent providing overlapping IVD, genetic, and molecular diagnostic testing services, though with vastly larger scale.
- BGI Genomics: China-headquartered genomics company offering clinical genetic testing, NIPT, and molecular diagnostics globally. Comparable as a broad incumbent with strong APAC presence in molecular and genetic diagnostics.
- Guardant Health: US-based precision oncology company specializing in liquid biopsy and NGS-based cancer testing. Comparable as a broad incumbent in oncology molecular diagnostics with overlapping product categories (e.g., HRD, cancer genomics).
Regional players
- Kingmed Diagnostics: China's leading independent clinical laboratory chain offering pathology, molecular diagnostics, and genetic testing. Comparable as an APAC-based clinical diagnostics provider, though primarily serving the Chinese market.
Emerging players
- Celemics: South Korea-based molecular diagnostics and genomics company offering NGS-based assays, including hereditary cancer panels. Comparable as an emerging Asia-focused molecular diagnostics provider in similar test categories.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
sciencewerkedx social profiles
Digital presencesciencewerkedx financial estimates
Financial estimateRevenue estimate
Valuation estimate
sciencewerkedx leadership team
Management profileNumber of profiles
sciencewerkedx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
sciencewerkedx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about sciencewerkedx
What does sciencewerkedx do?
SciencewerkeDX is a division of Sciencewerke Pte Ltd that distributes proprietary genetic, molecular, pharmacogenomic, enteric, and neurostimulation diagnostic products supplied by partner diagnostic companies. Its portfolio supports doctors, hospitals, patients, and families with tests for cancer risk and prognosis, psychiatric medication optimization, rare genetic disorders, enteric disease, depression treatment, radiotherapy treatment planning, and veterinary pathogen detection.
Is sciencewerkedx a public or private company?
sciencewerkedx is a private company. It is classified as corporate owned and is currently operating.
When was sciencewerkedx founded?
sciencewerkedx was founded in 2005.
Where is sciencewerkedx based?
sciencewerkedx is headquartered in Singapore, Singapore, in the Asia region.
How does sciencewerkedx make money?
One revenue line is on record: diagnostic Test Distribution.
Who are sciencewerkedx's main competitors?
Direct peers on record are Prenetics, Mirxes, ACT Genomics, Macrogen and Novogene. Broad incumbents are Eurofins Scientific, BGI Genomics and Guardant Health. Kingmed Diagnostics is listed as a regional player. Celemics is listed as an emerging player.
Does sciencewerkedx have an API?
No public API is recorded for sciencewerkedx.
What industry is sciencewerkedx in?
sciencewerkedx's product category is Medical Diagnostic Services. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 325413 and its SIC code is 2835.